Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis

NCT07726147 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergen Immunotherapy

Interventions

DRUG: ITI-9001
OTHER: Placebo

Sponsor

Immunomic Therapeutics, Inc.